News

Enteris continues to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma® platforms Received two milestone payments totaling $15 million from Cara Therapeutics per license […]

Boonton, NJ, January 10, 2022  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]

Oral Presentation Delivered at the American Society for Reproductive Medicine Scientific (ASRM) 2022 Congress & Expo Boonton, NJ, October 26, 2022  — Enteris BioPharma, Inc., a biotechnology […]

Physicochemical properties of peptides can provide key insights to potential success of oral delivery Boonton, NJ, September 07, 2022  — Enteris BioPharma, Inc., a biotechnology company developing […]

Article describes Enteris’ strengths and scalability in working with highly potent active pharmaceutical ingredients Boonton, NJ, August 03, 2022  — Enteris BioPharma, Inc., a biotechnology company developing […]

Boonton, NJ, July 14, 2022  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]

Data suggest that oral formulations of leuprolide developed utilizing Enteris’ Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal suppressive effects which are comparable to parenteral administration.